Home » Stocks » Evelo Biosciences

Evelo Biosciences, Inc. (EVLO)

Stock Price: $4.81 USD 0.06 (1.26%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 221.92M
Revenue (ttm) n/a
Net Income (ttm) -87.93M
Shares Out 46.14M
EPS (ttm) -2.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $4.81
Previous Close $4.75
Change ($) 0.06
Change (%) 1.26%
Day's Open 4.68
Day's Range 4.57 - 4.90
Day's Volume 46,969
52-Week Range 3.01 - 8.30

More Stats

Market Cap 221.92M
Enterprise Value 164.32M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 46.14M
Float 14.79M
EPS (basic) -2.72
EPS (diluted) -2.73
FCF / Share -2.35
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.73M
Short Ratio 12.41
Short % of Float 11.73%
Beta 0.81
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.17
Revenue n/a
Operating Income -87.67M
Net Income -87.93M
Free Cash Flow -76.72M
Net Cash 57.60M
Net Cash / Share 1.25
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -45.64%
ROE -103.87%
ROIC -257.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 2
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(101.04% upside)
Current: $4.81
Target: 9.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-86.36-58.10-27.53-13.03
Net Income-85.47-56.95-28.05-13.33
Shares Outstanding32.0321.873.752.83
Earnings Per Share-2.67-2.78-9.10-5.28
Operating Cash Flow-71.98-47.28-23.27-12.31
Capital Expenditures-3.03-5.29-1.74-1.22
Free Cash Flow-75.01-52.57-25.01-13.54
Cash & Equivalents77.8314838.2515.54
Total Debt19.6312.319.979.93
Net Cash / Debt58.2013628.285.61
Book Value60.20137-54.72-28.34
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Evelo Biosciences, Inc.
Country United States
Employees 98
CEO Balkrishan Gill

Stock Information

Ticker Symbol EVLO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EVLO
IPO Date May 9, 2018


Evelo Biosciences, a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a monoclonal microbial candidate, which is in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of psoriasis or atopic dermatitis. The company is also developing monoclonal microbial candidates, which are in pre-clinical development stage include EDP1815 for treating psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis; EDP1867 for asthma; EDP2939 for inflammatory disease; and EDP1632 for neuro-inflammatory diseases. In addition, it is developing EDP1503, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.